Before NAC, the nonluminal breast cancer with poor response to chemotherapy showed relatively low expression of E-cadherin and β-catenin and relatively high expression of CD44 and N-cadherin compared to the MHR group. The gene discussed is CDH2; the disease is breast cancer.